Advancing Respiratory Medicine Following ATS – What Now?

The energy coming out of this year’s ATS meeting was unmistakable: respiratory medicine is entering a new era of scientific ambition, cross‑industry collaboration, and patient‑centred innovation. Across the field, companies signalled a clear message: the momentum cannot stop here.

From breakthrough discussions on airway inflammation and precision‑guided therapies to renewed commitments to tackling the global burden of COPD, the post‑ATS landscape has set the stage for what comes next. Leaders across pharma and biotech echoed the same sentiment seen across LinkedIn in recent weeks: we must accelerate the translation of science into meaningful therapies for patients who have waited far too long.

That is exactly why the COPD Drug Development Summit is launching this September in Boston.

Why COPD Drug Development Summit?

• Industry-led expertise: As an industry-led platform, we are gathering 65+ respiratory experts from AstraZeneca, Sanofi, J&J, Merck, SMS Biotech, Alveolus Bio and others
• High value networking: An intimate setting with 7+ hours of in person networking with our poster session, dedicated networking breaks and more to re-energise COPD innovation, providing a platform to deepen cross sector collaboration

If you have left ATS feeling energised, join us in September to continue this conversation with industry leaders from discovery through late‑stage development.

Together, we will explore how emerging modalities, smarter trial design, and more precise endpoints can unlock the next generation of COPD therapies, and much more.

If you want to connect, meet biotech and pharmaceutical decision-makers, and hear first-hand on practical strategies being used to reduce development risk, accelerate clinical proof‑of‑concept, and deliver meaningful benefit to heterogeneous COPD patient populations, download the brochure now to see full event details.

If you’d like to learn more about which sessions best suit your role or company, or need help with registration, please don’t hesitate to reach out to us.